Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

BACKGROUND: Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) is active as a combination therapy in multiple tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N., Jay Ramsey, W., Kennedy, Eugene, Mautino, Mario R., Link, Charles J., Lin, Ray S., Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M., Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H., Janik, John E., Khleif, Samir N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009946/
https://www.ncbi.nlm.nih.gov/pubmed/29921320
http://dx.doi.org/10.1186/s40425-018-0351-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009946/
https://www.ncbi.nlm.nih.gov/pubmed/29921320
http://dx.doi.org/10.1186/s40425-018-0351-9

Ejemplares similares